Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.
Allakos Price Performance
NASDAQ ALLK opened at $0.25 on Monday. The business has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $0.90. The stock has a market capitalization of $22.69 million, a PE ratio of -0.13 and a beta of 0.86. Allakos has a fifty-two week low of $0.23 and a fifty-two week high of $1.69.
Allakos (NASDAQ:ALLK – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. As a group, sell-side analysts expect that Allakos will post -1.16 earnings per share for the current year.
Hedge Funds Weigh In On Allakos
Allakos Company Profile
Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
Featured Stories
- Five stocks we like better than Allakos
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Why Invest in High-Yield Dividend Stocks?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.